Nucleic Acid-Guided Nucleases (2017)
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 4 of these applications claim priority to application 15/632,001, filed Jun 23, 2017. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 9,982,279 | Nucleic Acid-Guided Nucleases In force · High confidence | Manus Inscripta, Inc. | In force | High confidence | ||
| US 10,337,028 | Nucleic Acid-Guided Nucleases In force · High confidence | Manus Inscripta, Inc. | In force | High confidence | ||
| US 11,408,012 | Nucleic Acid-Guided Nucleases In force · Medium confidence | Manus Inscripta, Inc. | In force | Medium confidence | ||
| US 12,180,502 | Nucleic Acid-Guided Nucleases In force · Medium confidence | Manus Inscripta, Inc. | In force | Medium confidence | ||
| US 11,697,826 | Nucleic Acid-Guided Nucleases In force · Medium confidence | Manus Inscripta, Inc. | In force | Medium confidence | ||
| Application 18/953,294 | Nucleic Acid-Guided Nucleases Pending Not granted | Manus Inscripta, Inc. | Pending | Not granted | not computed |
6 of 6 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
5 of these are in force and held by Manus Inscripta, Inc..
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.